Zealand Pharma Undertakes Share Capital Increase
In a strategic move to boost its capital, Zealand Pharma A/S, a pioneering biotechnology firm specializing in peptide-based medicines, has announced a significant share capital increase. This decision, emanating from the Board of Directors, reflects a nominal rise of DKK 20,924, resulting in the issuance of 20,924 new shares, each valued at DKK 1.
Employee Warrants Program and its Impact
Zealand Pharma's initiative is directly tied to the exercise of employee warrants, a key component of their incentive structure aimed at rewarding and motivating employees. Each warrant enables holders to acquire one newly issued share at a predetermined exercise price. This approach not only aligns employee interests with company performance but also supports a culture of commitment and innovation within the organization.
Capital Raise Details
The newly issued shares come with a defined exercise price of DKK 90.70 for each share, generating total proceeds of approximately DKK 1,897,806.80 for Zealand Pharma. This fresh influx of capital is expected to provide additional resources to further enhance their research and development efforts. As with the issuance of new shares, holders will gain rights to dividends and voting privileges from the moment they exercise the warrants.
Future Trading and Company Position
Once the necessary registrations with the Danish Business Authority are completed, these new shares will be eligible for trading on Nasdaq Copenhagen. Following this process, Zealand Pharma will see an updated share capital standing at DKK 71,364,728, divided into 71,364,728 shares, further solidifying its market presence and investment attractiveness.
Company Overview
Founded in 1998 and headquartered in Copenhagen, Zealand Pharma is not just a key player in Denmark’s biotech sector, but it also holds a strong position in the United States. The company’s portfolio is rich with innovative drug candidates, significantly more than ten of which are now in clinical stages, including two that have achieved market status. Zealand's commitment to enhancing patient care through effective peptide medicines is unwavering.
Investing in Future Innovations
The enterprise has established numerous partnerships with leading pharmaceutical companies, a move that amplifies its research capabilities and broadens the potential for commercial success. Zealand’s strategic alliances also play a crucial role in the company's mission to develop treatments that address pressing medical needs.
Contact for Investor Relations
For inquiries regarding investment and investor relations, key contacts at Zealand Pharma include:
Adam Lange, Vice President, Investor Relations. Correspondence can be directed to alange@zealandpharma.com.
Neshat Ahmadi, Investor Relations Manager, available at neahmadi@zealandpharma.com.
Anna Krassowska, PhD, Vice President, Investor Relations & Corporate Communications, can be reached at akrassowska@zealandpharma.com.
Frequently Asked Questions
What led to the capital increase by Zealand Pharma?
The capital increase was driven by the exercise of employee warrants, providing additional funds to support the company's initiatives.
How many new shares were issued?
A total of 20,924 new shares were issued, each with a nominal value of DKK 1.
What will the proceeds from the capital increase be used for?
The proceeds will be allocated to further research and development activities to enhance Zealand Pharma's innovative capabilities.
Where will the new shares be traded?
Once registered appropriately, the new shares will be listed and traded on Nasdaq Copenhagen.
Who can I contact for investor relations inquiries?
For any investor relations inquiries, you can reach Adam Lange, Neshat Ahmadi, or Anna Krassowska through the provided email addresses.
